Business description
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with brain disease. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at diseases such as depression and anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and Parkinson’s diseases.
Management board & Supervisory board
| CEO |
| Charl van Zyl |
| Management board |
| Joerg Hornstein, Lars Bang, Johan Luthman, Thomas Gibbs, Michala Fischer-Hansen, Dianne Hol, Tine Østergaard Hansen |
| Supervisory board |
| Lars Rasmussen, Dorothea Wenzel, Jeffrey Berkowitz, Lars Holmqvist, Lene Skole-Sørensen, Santiago Arroyo, Jakob Riis, Camilla Gram Andersson, Dorte Clausen, Lasse Skibsbye |
Company data
| Name: |
H. Lundbeck A/S |
| Address: |
Ottiliavej 9,DK-2500 Valby |
| Phone: |
+45-3630-1311 |
| Fax: |
+45-3630-1940 |
| E-mail: |
information@lundbeck.com
|
| Internet: |
www.lundbeck.com/ |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
12-31 |
| Free Float: |
31.00% |
| IPO date: |
- |
Investor relations
| Name: |
Palle Holm Olesen |
| IR phone: |
+45-3083-2426 |
| IR Fax: |
- |
| IR e-mail: |
PALO@Lundbeck.com
|
